Skip to main content

International Journal of Pharmaceutics Publishes Study on the NanoZolid® Technology for Local Release of Biomolecules

Written by Customer Service on . Posted in Public Companies.

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the journal International Journal of Pharmaceutics has accepted a biomolecule study from LIDDS for publication. The investigation has been performed in collaboration with the Karolinska Institute in Huddinge, Sweden and Truly labs in Lund, Sweden. The study confirms that proteins are released from NanoZolid® depots with maintained bio-functionality, illustrated by protein targeting to tumor cell receptors. The investigation was performed with fluorescence-imaging.

                                                   

The NanoZolid® technology has during the last years been shown to enable a controlled release of a wide range of drugs following a single injection, resulting in stable and pharmacologically validated effects over a desired time period. In this study, a fluorescence-labelled model substance, Epidermal Growth Factor (EGF) protein, was used and followed longitudinally in mice after subcutaneous injections of the NanoZolid depot implants. The labelled EGF accumulated in tumors that express receptors for EGF in the hind leg. The molecule size of EGF protein is 6 kDa which is similar with other polypeptides and smaller proteins relevant for anti-cancer treatment.

“We are delighted that the study results will be published in this prestigious journal marking an important cornerstone in showing the ability of NanoZolid® technology to address the challenges with systemic or local longer-term treatments of larger biomolecules. It also opens up new partnering possibilities as the acceptance of the study is an independent validation of our technology,” said Monica Wallter, CEO of LIDDS.

NanoZolid® depot formulated biological drugs for slow release offer the possibility to overcome issues with systemic or local frequent treatments and compliance. There is a large need for this type of technology in a diverse range of disease areas, including cancer, psychiatric, endocrine and autoimmune diseases. NanoZolid® depot for local release, e.g. intratumoral delivery of drugs, offers less injections, a decreased risk for systemic adverse effects and an increased quality of life.

The publication has the title “Biodistribution of fluorescence-labelled EGF protein from slow release NanoZolid depots in mouse” and will be found at:
https://www.sciencedirect.com/journal/international-journal-of-pharmaceutics

when published, which is expected in a few weeks.

For more information, please contact:

Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: monica.wallter@liddspharma.com

                                                                                                       

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North (LIDDS). Redeye AB is the Certified Adviser to LIDDS (+46 (0) 8 121 576 90, email: certifiedadviser@redeye.se) For more information, please visit www.liddspharma.com.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.